Importantly, in paired biopsies obtained from patients with BRAF-mutant melanoma before treatment and after initiation of BRAF inhibitor therapy, the suppression of S6 phosphorylation was found to be predictive of improved progression-free survival. This evidence concerns the gene BRAF and melanoma.